02 · Clinical Findings
A review raises a careful question about GLP-1 medicines and binge eating
A UCL-led review points to symptom reduction while keeping the next proof step in view.
A review of 25 randomized trials involving 8,069 people found that GLP-1-targeting medicines were associated with fewer binge-eating episodes, less loss-of-control eating, and less emotional eating. The studies covered several medicines and countries, but they did not establish an approved treatment for binge-eating disorder.
The signal matters because binge-eating disorder has limited medication options and can be deeply impairing. Most of the trials, however, did not enroll people with a clinical diagnosis of the disorder, so the result cannot predict how a person with that diagnosis will respond.
The next proof step is longer, independently funded trials that enroll people diagnosed with binge-eating disorder and follow both benefits and restrictive-eating risks. Until then, the evidence supports a research question, not a treatment instruction.
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Combining two diabetes drug classes is not automatically a bigger clinical benefit
At the highest dose, retatrutide cut 21% of body weight in people with type 2 diabetes
Tirzepatide kept nearly 99% of prediabetes patients diabetes-free over three years
Continue reading · Clinical FindingsPeptide News / Clinical FindingsThe firmest GLP-1 mental health evidence sits in depression and alcohol usePsychology Today · Jul 9, 2026 · scroll to read